Can Vertex turn its $10bn Crinetics deal into a rare endocrinology powerhouse?
Discover why Vertex is paying $10 billion for Crinetics and how Palsonify and atumelnant could reshape rare endocrine treatment.
Pharma & Biotech
Pharma & Biotech
Camurus Oclaiz CRL shows how one manufacturing site can stall a differentiated endocrine therapy
Find out how Camurus’ fresh FDA setback for Oclaiz could delay its U.S. acromegaly launch and reshape rare disease manufacturing risk.
Pharma & Biotech
Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody
Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.
Pharma & Biotech
Camurus’s FDA review restart for Oclaiz puts long-acting octreotide on track for a potential U.S. launch in mid-2026
Camurus AB announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of the New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly. The agency assigned a Prescription Drug User Fee Act (PDUFA) action date of June 10, 2026, reinitiating regulatory review after an earlier Complete Response Letter related